The mucosal barrier, found lining epithelial cells, serves multiple functions in a range of animals. 16
expression of several mucins, including MUL-1, increased upon P. aeruginosa infection of the 23 nematode Caenorhabditis elegans, silencing of or deletion of mul-1 resulted in enhanced 24 survival and reduced bacterial accumulation. P. aeruginosa required host sialidase CTSA-1.1 to 25 use mucin-derived glycans to colonize the host, while sialidase-encoding bacteria required host 26 MUL-1 but not CTSA-1.1 to cause a lethal infection. This role of mucins and free glycans in 27 host-pathogen interaction appears to be conserved from C. elegans to humans, as P. aeruginosa 28 binding to human lung epithelial cells was also enhanced in the presence of free glycans, and 29 free glycans reversed the binding defect of P. aeruginosa to human lung cells lacking the mucin 30 MUC1. 31
Introduction.
Alterations in mucin expression or glycosylation patterns have been linked to various 78 pathologies and diseases, including cystic fibrosis, chronic obstructive pulmonary disease, 79 cancers, and inflammatory bowel disease (1) . These diseases, that are linked to changes in mucin 80 expression, glycosylation patterns, and alterations in mucus levels, are associated with higher 81 rates of infection with opportunistic pathogens (2, 16, 17) . Increases in mucus levels often result 82 in a more highly viscous material that is not readily cleared from the mucosal barrier. Decreases 83 in mucus levels remove the protective barrier, which allows pathogens to have direct access to 84 epithelial cells. Many of the diseases linked to alterations in mucus levels have no known cure, 85 and the primary mode of treatment involves controlling mucin expression, which is a key method 86 used to prevent bacterial infections associated with these diseases (16, 18) . A better 87 understanding of the mechanisms by which pathogens utilize mucins will provide novel 88 approaches to control infectious processes and prevent bacterial colonization. 89
The complexity of mammalian epithelial mucosal surfaces and the additional functions of 90 the innate immune system can mask the roles of individual mucins at epithelial barriers. Using 91 the model organism, Caenorhabditis elegans, we can tease apart the roles of individual mucins at 92 the intestinal epithelial barrier. This model provides the advantage of a simple organism's small 93 genome size and the absences of adaptive immunity. C. elegans eats bacteria found in 94 decomposing organic matter (19) . Several pathogens are present in the environment in which C. 95 elegans feeds, which can impair the growth of the nematode and induce stress responses, 96 ultimately leading to nematode death (20) . The ability to distinguish between pathogenic and 97 non-pathogenic microbes is critical for the survival of the nematodes and thus, C. elegans has 98 methods to recognize and counteract pathogens. One of these responses is the upregulation of 99 mucins during infection (21, 22) . 100
Herein we explore the role of mul-1 during pathogen infection and find that pathogens 101 use the immune factor to gain a competitive advantage in the host. We identified mul-1 as a 102 mucin, that when inhibited, enhances resistance to P. aeruginosa and S. enterica infection. This 103 is despite the fact that mul-1 gene expression is induced upon infection by these pathogens as 104 part of the general immune response. We further explored the role of the mucin during infection 105 and found that MUL-1 provides glycans that are required for attachment to C. elegans intestine 106 and that a similar mechanism is conserved in mammalian epithelial cells. These results indicate 107 that pathogens have evolved a mechanism to subvert conserved immune effectors to colonize 108 different hosts. 109 110 Results. 111 C. elegans lacking mul-1 exhibit enhanced resistance to P. aeruginosa infection. 112
Little is known about the roles of specific mucins in the C. elegans intestine during infection, but 113 several enzymes and transporters that modify the glycan patterns of mucins have been identified 114 to alter host-pathogen interactions. We set out to better understand the roles of specific intestine-115 expressed mucins during P. aeruginosa infection. The six identified mucins and mucin-editing 116 enzymes (Table S1) were silenced by RNAi and the survival of the animals was monitored 117 during P. aeruginosa PA14 infection. Upon analysis, RNAi for two genes, mul-1 and gpdh -1, 118 resulted in enhanced resistance to pathogen infection and RNAi for one mucin, let-653, resulted 119 in enhanced susceptibility to pathogen infection (Table S1 and Figure S1 ). 120
Because mucins are upregulated upon infection and have been characterized as bona fide 121 immune effectors, the enhanced resistance phenotype for two of the genes was unexpected. The 122 most significant phenotype was observed for mul-1 RNAi animals, which showed enhanced 123 resistance to P. aeruginosa compared to RNAi control animals ( Figure 1A ). mul-1 mRNA 124 transcripts are found at high levels in the intestine (23) and it was previously shown that mul-1 is 125 upregulated upon infection with P. aeruginosa at 4 and 8 hours (21, 22) . Other upregulated genes 126 from those datasets include innate immune factors, which would suggest that mul-1 is an 127 immune response factor turned on to combat pathogen infection. 128 there were significantly fewer CFUs recovered per nematode after 4 hours ( Figure 1B ) and little 139 to no fluorescent signal was found in RNAi mul-1 animals compared to control RNAi animals at 140 24 hours post infection ( Figure 1C ). To determine if the enhanced resistance to P. aeruginosa 141 infection is a general phenotype in the mul-1 RNAi animals, we exposed these animals to 142
Salmonella enterica ser Typhimurium ST1344 and monitored survival. The enhanced resistance 143 phenotype was also observed when the RNAi mul-1 nematodes were exposed to full lawns of S. 144 enterica. RNAi mul-1 nematodes lived longer upon exposure to S. enterica than RNAi control 145 nematodes (Supplementary Figure 1A) and accumulated fewer S. enterica bacteria 146 (Supplementary Figure 1B and 1C) . 147
Because of the increase in survival upon pathogen exposure observed in mul-1 RNAi 148 animals, we studied if differences in the lifespan of the mul-1 RNAi animals may be responsible 149 for the enhanced survival in the presence of P. aeruginosa. As shown in Figure 1D , the longevity 150 of mul-1 RNAi animals was indistinguishable from that of control animals, ruling out that the 151 possibility that enhanced longevity was the cause of enhanced survival in the presence of 152 pathogenic bacteria. To confirm the roles of mul-1 during infection, an in-frame, full gene 153 deletion strain was used. The mul-1(ac7) strain also showed enhanced resistance to P. 154 aeruginosa ( Figure 1E ), significantly fewer CFUs per nematode ( Figure 1F ), and there was no 155 difference in lifespan in comparison to wildtype N2 nematodes ( Figure 1G ). 156
Expression of mul-1 has been reported in the intestine, hypodermis, and PVD and OLL 157 neurons (23,24). To address whether intestinal mul-1 is specifically contributing to infection, 158 intestine-specific RNAi was performed using two intestine-specific RNAi strains, VP303 (25) 159 and MGH171 (26). In both cases, we found that mul-1 RNAi in the intestine resulted in enhanced 160 resistance to P. aeruginosa (Figure 2A and 2B). 161
One of the possible explanations for the mul-1 RNAi animals' enhanced resistance to P. 162 aeruginosa could be due to the increased expression of other intestinal-expressed mucins that 163 compensate for the loss of MUL-1. To rule out the possibility that other mucins are upregulated 164 to compensate for the loss of mul-1, qRT-PCR was performed on RNAi control vector and RNAi 165 mul-1 nematodes. When the RNAi mul-1 nematodes were grown on non-pathogenic E. coli, 166 there were some statistically significant increases in expression levels of the intestine-expressed 167 mucins and mucin-related enzymes compared to RNAi control nematodes. (Figure 3 ). Many of 168 the significant increases found when the nematodes were grown on E. coli were no longer 169 observed in mul-1 RNAi nematodes grown on P. aeruginosa compared to control animals also 170 exposed to P. aeruginosa. We don't think these less than threefold increases could account for 171 the enhanced resistance phenotype of the mul-1 RNAi animals. 172
We have shown that mul-1 RNAi animals are not colonized by P. aeruginosa during 173 infection. Recent work shows that colonization by P. aeruginosa and other pathogens causes 174 bloating of the intestine that results in the expression of innate immune effectors and the 175 elicitation of a pathogen avoidance behavior (27). Because the mul-1 mutant has limited bacterial 176 accumulation in the intestine, we hypothesized that these animals would not bloat and thus 177 would not avoid P. aeruginosa. C. elegans strains were exposed to partial lawns of P. 178 aeruginosa PA14 and lawn occupancy was characterized at 24 hours. Consistent with the 179 previous study, over 80% of the wild type N2 animals were outside of the P. aeruginosa PA14 180 lawn, demonstrating that wild type animals avoid P. aeruginosa ( Figure 4A ). In comparison, 181 only 16.8% of the mul-1 (ac7) animals were outside of the bacterial lawn (83.2% lawn 182 occupancy), suggesting that the mutant animals do not avoid P. aeruginosa. Because the mul-1 183 (ac7) animals do not avoid, it would be presumed that the animals have enhanced ingestion of P. 184 aeruginosa and die more rapidly than wild type animals. Although the mul-1 (ac7) animals don't 185 avoid P. aeruginosa, they still demonstrate an enhanced resistance to the pathogen in comparison 186 to wild type when survival was monitored on partial lawns of P. aeruginosa ( Figure 4B ). 187 188 Mucin-derived glycans are required for successful P. aeruginosa infection. 189
Based on our data that shows mul-1 (ac7) and mul-1 RNAi animals are not colonized by P. 190 aeruginosa, we hypothesized that MUL-1 plays a beneficial role for pathogens in the host. This 191 is contrary to the idea that MUL-1 is a C. elegans innate immune effector used by the nematode 192 to fight and clear infections. To better understand the role of MUL-1 inside the C. elegans 193 intestine, we probed whether P. aeruginosa is able to access glycans from MUL-1 in the C. 194 elegans intestine. 195
In certain cases, pathogens have been reported to utilize glycans such as O-linked 196 oligosaccharides from mucins (28-30), but in order to expose the host glycans, bacteria require a 197 sialidase enzyme to cleave the sialic acid cap from host polysaccharides. P. aeruginosa does not 198 encode a bacterial sialidase, thus we questioned if C. elegans expresses an enzyme that performs 199 a similar function to process polysaccharides for P. aeruginosa use. C. elegans encodes CTSA-200 1.1, a homolog to human cathepsin A, which is predicted to have serine-type carboxypeptidase 201 activity. This enzyme is predicted to have neuraminidase activity, which hydrolyzes terminal 202 sialic acid residues on polysaccharide chains, most often exposing a galactose residue. The 203 neuraminidase is expressed in the intestine, but does not change expression upon pathogen 204 infection [21, 31, 32] . To determine if the neuraminidase contributes to the enhanced resistance to 205 P. aeruginosa infection, RNAi for ctsa-1.1 was performed. RNAi ctsa-1.1 significantly enhanced 206 resistance, but not to the same extent as mul-1 RNAi ( Figure 5A ). Co-RNAi for both mul-1 and 207 ctsa-1.1 was not additive, which suggests that these two gene products contribute to the same 208 mechanism by which P. aeruginosa establishes an infection and kills C. elegans. There was no 209 difference in PA14 accumulation in the RNAi mul-1, RNAi ctsa-1.1, or co-RNAi, but all three 210 conditions resulted in significantly fewer CFUs per nematode compared to RNAi control ( Figure  211 5B). To confirm that the enhanced resistance to P. aeruginosa phenotype was not due to 212 enhanced longevity, we studied the mul-1 RNAi, ctsa-1.1 RNAi, and co-RNAi nematode 213 lifespan. There were no differences in lifespan under all RNAi conditions ( Figure 5C ). 214
Because the mul-1 RNAi enhanced resistance phenotype was observed for both P. sialidases that allow the bacteria to access glycan molecules from mucins (31). Thus, the C. 222 elegans enzyme may not be required by S. enterica during infection. The use of the C. elegans 223 enzyme, CTSA-1.1 appears to be specific to P. aeruginosa, which lacks a sialidase. 224
To further elucidate the mechanism(s) by which mucins benefit pathogens during 225 infection, we tested if individual purified free glycans had any effect on bacterial growth. We 226 also wanted to determine if free glycans had any impact on C. elegans survival on P. aeruginosa. 227
Based on previous studies that aimed to understand the impact of mucin glycosylation patterning 228 on development and infectious disease, we identified several o-linked glycans that may be 229 important for bacterial binding and or growth in vivo in the nematode. These included N-230 acetylgalactosamine, galactose, N-acetylglucosamine, and N-acetyl neuraminic acid, which is the 231 predominant sialic acid found in mammalian mucin glycan chains (32-34). Commercially 232 available free glycans were added to Luria Broth (LB) to assess their effect on PA14 growth. 233
There were no significant changes to bacterial growth in LB (Supplemental Figure 3A ). We also 234 tested the effects of these free glycans in a minimal bacterial growth media, M9 media, because 235 LB media is rich and provides ample carbon source(s) for the bacteria, and in LB media we may 236 not observe any additional enhancement to growth. None of the free glycans had any effect on 237 bacterial growth in M9 media over the course of 48 hours. In fact, we observed little to no 238 growth of the bacteria in M9 media or M9 media supplemented with glycans (Supplemental 239 Figure 3B ), and it was not until 72 hours that we observed statistically enhanced growth of the P. 6D), which suggests that P. aeruginosa specifically utilizes N-acetyl-D-galactosamine from 253
MUL-1 during infection. 254
To determine whether the pathogens must be exposed to the free glycans during 255 infection, or whether the free glycans cause a long-lasting increase in virulence of the pathogens, 256 bacteria were first cultured in the presence of free glycans at concentrations used on the plates 257 used in killing assays. Bacteria were then collected and used to seed full lawn plates, on which 258 survival for the RNAi control and RNAi mul-1 nematodes was tested. Addition of the free 259 glycans, N-acetyl-D-glucosamine ( Figure 6E ) and N-acetyl-D-galactosamine ( Figure 6F ), to the 260 media prior to seeding had no effect on nematode survival on PA14 lawns. This suggests that the 261 free glycans must be present and possibly absorbed by the bacteria as entering the nematode, or 262 absorbed by the nematodes, so that the bacteria have access to the glycans once inside the 263 nematode intestine. used to assess bacterial binding in the presence of free glycans because these cells express 280 MUC1 and MUC5a mucins based upon mRNA transcript profiling (37,38). We reasoned that the 281 use of this cell culture model system, with only 2 mucins, would make it simpler to distinguish 282 which specific human mucin is involved in the binding phenotypes observed. The A549 human 283 lung alveolar cells were seeded and grown for approximately 24 hours until 80% confluency. 2 284 mM free glycans were added to cultures at the same time as bacteria were added. Mid log-phase 285 P. aeruginosa PA14 were added to cell cultures at a Multiplicity of Infection (MOI) of 100 and 286 at 4 hours, bacterial binding was assessed. Both N-acetyl-D-glucosamine and N-acetyl-D-287 galactosamine significantly increased bacterial adherence ( Figure 7A ). 288
To determine if the free glycans are required to be processed by the cells prior to use by 289 P. aeruginosa, 2 mM free glycans were added to A549 Lung cells at the time of seeding and 290 remained present for the ~24 hours prior to bacteria were added. P. aeruginosa was again added 291 at an MOI of 100 to cells and bacterial binding was measured at 4 hours. When glycans were 292 added at the time of cell seeding, we saw that bacterial binding ( Figure 7C ) was increased for 293 cells supplemented with both N-acetyl-D-glucosamine and N-acetyl-D-galactosamine. 294
We have shown that free glycans, specifically N-acetyl-D-galactosamine, can supplement 295 for MUL-1 during P. aeruginosa infection of C. elegans. In order to determine if these free 296 glycans are able to supplement for mucins in human lung cells, siRNA silencing (lentiviral 297 transfection) was used to knock down expression of human muc1 in A549 human lung cell 298 model. Knockdown did not result in any growth defects of the cells, but it reduced the number of 299 bacteria bound per cell ( Figure 8 ). This is similar to observations in C. elegans, suggesting that 300 mucins and glycans play similar roles in different models of bacterial pathogenesis. Thus, as 301 expected, when N-acetyl-D-glucosamine and N-acetyl-D-galactosamine were added to control 302 and muc1 siRNA knockdown they enhanced bacterial binding. Both free glycans increased 303 binding of P. aeruginosa to the control A549 lung cells when the glycans were added to the 304 media at the same time as the bacteria (Figure 8 ). The free glycans also reversed the binding 305 defect of P. aeruginosa to muc1 siRNA knockdown cells, restoring the number of bacteria per 306 cell to that of control cells in media alone (Figure 8 ). 307 308
Discussion. 309
This work details the ability of the pathogen P. aeruginosa to use mucin-derived glycans to 310 successfully colonize mucosal epithelial barriers. Our data shows that silencing or deleting a 311 pathogen-induced immune effector gene, mul-1, results in enhanced resistance to P. aeruginosa. 312
These results were unexpected because we and others have shown that mul-1 expression is 313 increased upon pathogen infection as part of a general immune response (21, 22) . Understanding 314 the mechanisms by which P. aeruginosa binds to and obtains resources from various mucins 315 may provide a better understanding of host-pathogen interactions and allow for the development 316 of targeted therapeutics. 317 P. aeruginosa is able to utilize mucin-derived glycans to colonize the host, which we 318 have demonstrated by adding free glycans to C. elegans growth media during infection. We have 319
shown that one specific glycan, N-acetyl-D-galactosamine, had no effect on control nematodes, 320 but rescued the enhanced resistance phenotype of the mul-1 RNAi nematodes. This phenomenon 321 appears to be conserved from C. elegans to humans, as P. aeruginosa binding to human lung 322 epithelial cells was also enhanced in the presence of free glycans, and free glycans reversed the 323 binding defect of P. aeruginosa to muc1 siRNA human lung cells. 324
In addition to enhanced resistance to P. aeruginosa infection, resistance to S. enterica is 325 enhanced upon silencing of mul-1, which suggests that the use of mucin-derived glycans may be 326 a conserved mechanism by a variety of pathogens that infect mucosal epithelial barriers. In order 327 to fully understand the specific role that mul-1 plays for pathogens during infection, we tested the 328 ability of P. aeruginosa and S. enterica to access free glycans from MUL-1 during infection. In 329 order for bacteria to access glycans from mucins, pathogens must first enzymatically cleave the 330 sialic acid cap from the end of polysaccharide chains. Both pathogens have been reported to use 331 free glycans as carbon sources, but only S. enterica encodes and expresses a bacterial sialidase 332 (28,30). C. elegans encodes an enzyme, ctsa-1.1, that is predicted to perform a similar enzymatic 333 function as bacterial sialidases, has a predicted secretion signal, and is expressed in the intestine. 334
We have shown that RNAi silencing of ctsa-1.1 results in enhanced resistance to P. aeruginosa 335 but not enhanced resistance to S. enterica. This suggests that S. enterica is able to use its 336 bacterial-encoded sialidase to gain access to glycans, but P. aeruginosa cannot access glycans 337 without the C. elegans enzyme. It is possible that other intestinal mucins serve similar roles in 338 binding and acting as a carbon source for pathogens, which may depend upon the composition of 339 the glycan chains of the mucin and the specific use of the glycans by the pathogens. 340
One of the most interesting implications of our data is that while mul-1 expression is 341 enhanced upon C. elegans infection with P. aeruginosa and S. enterica, the animals would 342 apparently be at an advantage without mul-1 during infection with P. aeruginosa and S. enterica. 343
The bacteria are able to access the glycans present on the glycan chains by using either host-344 expressed or bacterial expressed sialidase enzymes. These glycans aid in the colonization of the 345 host, suggesting that despite the fact that MUL-1 in an innate immune response factor, pathogens 346 have evolved to use this mucin and the glycans that decorate the peptide. The ability to control a 347 pathogen's access to mucins and the provided glycans could prove to be a method to prevent 348 and/or disrupt infection. In certain disease states, opportunistic pathogens are able to colonize 349 and establish an infection when there are changes in the levels of mucus and expression levels of 350 mucins. In some cases, only the glycosylation patterns of mucins change and this provides 351 enhanced binding for pathogens. If there were therapeutics available to prevent binding of 352 pathogens to mucin oligosaccharides or to control mucin expression, this would be extremely 353 beneficial in treating disease and could prevent opportunistic pathogen infection. 354
355
Acknowledgements 356
None. 357
Methods 358
Bacterial Strains 359
The following bacterial strains were used: Escherichia coli OP50, E. coli HT115 (DE3), 360
Pseudomonas aeruginosa PA14, P. aeruginosa PA14-GFP, Salmonella enterica serovar 361 Typhimurium 1344. All strains were grown on Luria-Bertani (LB) agarose plates or LB broth at 362 37ºC shaking at 250 RPM. Fluorescence imaging was carried out as described previously (42) . Briefly, animals were 440 anesthetized using an M9 salt solution containing 30 mM sodium azide and mounted onto 2% 441 agar pads. The animals were then visualized using a Leica 442 M165 FC fluorescence stereomicroscope. 443
444

RNA Isolation and Quantitative Reverse Transcription-PCR (qRT-PCR) 445
Animals were synchronized by egg laying. Approximately 35 N2 gravid adult animals were 446 transferred to 10-cm RNAi plates seeded with E. coli HT115 (DE3) expressing the appropriate 447 vectors and allowed to lay eggs for 8 hours. Gravid adults were then removed, and the eggs were 448 allowed to develop at 20ºC. For gene expression analysis in the P. aeruginosa infection assays, 449 the animals were first grown on 10-cm RNAi plates seeded with E. coli HT115 expressing either 450 the empty vector RNAi control or mul-1 RNAi until the young adult stage. Subsequently, the 451 animals were collected, washed with M9 buffer, and transferred to 10-cm modified NGM plates 452 (3.5% instead of 2.5% peptone) seeded with 300 µL of P. aeruginosa culture grown overnight. 453
The P. aeruginosa plates were prepared by spreading 300 µL of the P. aeruginosa culture on the 454 surface of the modified NGM plates, followed by an overnight incubation at 37ºC. After transfer 455 of the animals, the P. aeruginosa plates were incubated at 25ºC for 8 hours. Animals on the 456 control E. coli plates were also incubated at 25ºC. After the desired treatment, the animals were 457 collected, washed with M9 buffer, and frozen in TRIzol reagent (Life Technologies, Carlsbad, 458 CA). Total RNA was extracted using the RNeasy Plus Universal Kit (Qiagen, Netherlands). 459
Residual genomic DNA was removed using TURBO DNase (Life Technologies, Carlsbad, CA). Table S1 . The MISSION TRC shRNA Lentiviral Transfection protocol was used. 1 x 10 6 A549 cells were 510 plated in 60 mm dishes and grown 20 hours at 37ºC 5% CO2 to ~60-70% confluency. Media was 511 replaced without 8 µg/mL Hexadimethrine bromide. An MOI of ~0.5 (~13 µL of stock 512 lentivirus) was added to plates and incubated for 6 hours. Media was replaced without antibiotics 513 for 24 hours. The following day, media was replaced with medium containing 5 µg/mL 514 puromycin. Media was replaced with fresh puromycin containing media every 3-4 days until 515 resistant colonies grew to confluency. Cells were then used for indicated assays. 516 517
Gentamycin Protection Assay -Bacterial binding to cells 518
The gentamycin protection assay protocol was used, as previously described (43), with some 519 modifications (44). A549 cells were grown in 96-well plates with or without free glycans present 520 for 2 days at 37ºC, 5% CO2 until they reached approximately 85% confluency, corresponding to 521 1 x 10 5 cells per well. Wells were washed four times with sterile PBS and serum-free DMEM 522 F12 was added for 2 h. P. aeruginosa PA14 was grown overnight in LB at 37ºC shaking, diluted 523 1:10 and allowed to grow under the same conditions for 4 hours (obtaining mid-log phase 524 bacteria). A549 cells were infected with P. aeruginosa PA14 at an MOI of 100 and incubated for 525 2 hours at 37ºC, 5% CO2. From the original bacterial suspension, serial dilutions were plated 526 were prepared to verify the starting concentration of P. aeruginosa. Following incubation, the 527 supernatants were removed, the wells were washed four times with PBS, and the numbers of 528 associated or internalized bacteria were assessed as follows: 30 µL of 0.05% trypsin-EDTA was 529 added to each well, incubated for 2 min at 37ºC. Cells were lysed with 70 µL of 0.1% Triton X-530 100 for 2 min at 37ºC. Lysates were removed and serial dilutions were plated. Cell viability was 531 measured using Promega Cell-Titre Glo 2.0 reagent (quantitates cellular ATP levels) and CFUs 532 were normalized per cell under each condition. These results represent the number of both 533
Attached and Intracellular bacteria (CFU / # of cells). To quantify internalized bacteria, after the 534 4 hour incubation with P. aeruginosa PA14 and four PBS washes, 200 µg/mL gentamicin sulfate 535 in 50 µL of medium was added to each well and incubated for 90 minutes to eliminate 536 extracellular bacteria. After the incubation, supernatants were removed, and serial dilutions were 537 plated to quantitate the number of extracellular P. aeruginosa PA14 that may have survived 538 gentamycin treatment. A549 cells were then washed four times with PBS, trypsinized, and lysed 539 as described above; serial dilutions were performed and plated onto LB agar plates. Again, CFUs 540 were normalized to viable cells. The results represent the number of intracellular bacteria (CFU / 541 # of cells). 542
Quantification and Statistical Analysis 544
Statistical analysis was performed with Prism 7 (GraphPad). All error bars represent the standard 545 deviation (SD). The two-sample t test was used when needed, and the data were judged to be 546 statistically significant when p < 0.05. In the figures, asterisks (*) denotes statistical significance 547 as follows: *, p < 0.05, **, p < 0.001, ***, p < 0.0001, as compared to the appropriate controls. 548
The KaplanMeier method was used to calculate the survival fractions, and statistical significance 549 between survival curves was determined using the log-rank test. All experiments were performed 550 in triplicate. 551 552 Figure 1 . RNAi silencing and deletion of mul-1 results in an enhanced resistance phenotype 663 to P. aeruginosa PA14. (A) N2 wild-type animals were exposed to two generations of RNAi. 664
Young adult animals were transferred to full lawns of P. aeruginosa PA14 and nematode survival 665 intestine alters the resistance phenotype of C. elegans nematodes. (A) N2 wild-type animals 733
were exposed to two generations of RNAi targeting mul-1, F41C3.5, and an equal mixture of mul-734 1 and F41C3.5. Young adult animals were transferred to full lawns of P. aeruginosa PA14 and 735 nematode survival was monitored daily. Animals were considered dead upon failure to respond to 736 touch. Animals missing from the agar plate were censored on the day of loss. were used to create control and muc1 knockdown cells. Approximately 1 x 10 5 A549 lung cells 797 (~85% confluency) were grown for 2 days without glycans preset in the media. On the day of the 798 experiment, 2 mM N-acetyl-D-glucosamine or 2 mM N-acetyl-D-galactosamine was added to the 799 media at the same time as the cells were infected with an MOI of 100 for 4 hours with P. 800 aeruginosa PA14. Intracellular and extracellular bacteria were quantified, as described in methods. 801
Cells were not treated with gentamycin prior to isolating bacteria. Cell viability was measured 802
using Control siRNA muc1 siRNA p = 0.000549 p = 0.001058 p = 0.008770 p = 0.0035 n.s. p = 0.0013 p = 0.0101 Figure S4 . Free glycans have limited effects on P. aeruginosa growth in cell growth media. 852 Individual bacterial colonies were inoculated into 2 mL of LB and grown overnight, shaking at 853 225 RPM at 37ºC. Overnight cultures were diluted to an OD600 of 0.05 in DMEM F12+K + 10% 854
Heat-Inactivated FBS with varying concentrations of (A) N-acetyl-D-glucoasmine or (B) N-855 acetyl-D-galactosamine. 100 µL bacterial cultures were placed in individual wells of a 96 well 856 plate with various glycans added at indicated concentrations. Bacterial growth was monitored over 857 time by measuring the OD600 at indicated time points. 858
